PL2131841T3 - Sposoby leczenia bólu ostrego - Google Patents

Sposoby leczenia bólu ostrego

Info

Publication number
PL2131841T3
PL2131841T3 PL08724934T PL08724934T PL2131841T3 PL 2131841 T3 PL2131841 T3 PL 2131841T3 PL 08724934 T PL08724934 T PL 08724934T PL 08724934 T PL08724934 T PL 08724934T PL 2131841 T3 PL2131841 T3 PL 2131841T3
Authority
PL
Poland
Prior art keywords
methods
acute pain
treating acute
treating
pain
Prior art date
Application number
PL08724934T
Other languages
English (en)
Inventor
Kirk W Johnson
Linda Watkins
Mark Hutchinson
Original Assignee
Avigen Inc
Univ Colorado Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avigen Inc, Univ Colorado Regents filed Critical Avigen Inc
Publication of PL2131841T3 publication Critical patent/PL2131841T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL08724934T 2007-01-30 2008-01-29 Sposoby leczenia bólu ostrego PL2131841T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89836207P 2007-01-30 2007-01-30
PCT/US2008/001187 WO2008094571A1 (en) 2007-01-30 2008-01-29 Methods for treating acute and subchronic pain
EP08724934A EP2131841B1 (en) 2007-01-30 2008-01-29 Methods for treating acute pain

Publications (1)

Publication Number Publication Date
PL2131841T3 true PL2131841T3 (pl) 2013-03-29

Family

ID=39345258

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08724934T PL2131841T3 (pl) 2007-01-30 2008-01-29 Sposoby leczenia bólu ostrego

Country Status (8)

Country Link
US (1) US20080181876A1 (pl)
EP (1) EP2131841B1 (pl)
DK (1) DK2131841T3 (pl)
ES (1) ES2392116T3 (pl)
HK (1) HK1139856A1 (pl)
PL (1) PL2131841T3 (pl)
PT (1) PT2131841E (pl)
WO (1) WO2008094571A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1928438T3 (pl) * 2005-09-26 2013-08-30 Avigen Inc Zastosowanie ibudilastu do leczenia uzależnień od środków odurzających
CA2653345A1 (en) 2006-05-31 2007-12-13 Avigen, Inc. Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity
CA2669463A1 (en) * 2006-11-09 2008-05-15 Avigen, Inc. Method for treating delirium
WO2008137012A1 (en) * 2007-05-03 2008-11-13 Avigen, Inc. Use of a glial attenuator to prevent amplified pain responses caused by glial priming
CA2785056A1 (en) 2009-12-22 2011-07-21 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
US9693949B1 (en) 2015-12-22 2017-07-04 Revogenex Ireland Ltd Intravenous administration of tramadol
US9980900B2 (en) 2015-12-22 2018-05-29 Revogenex Ireland Ltd Intravenous administration of tramadol
EP3743145A4 (en) 2018-01-25 2021-12-15 Cognifisense, Inc. COMBINATORY THERAPEUTIC SYSTEMS AND PROCEDURES
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5229318B2 (pl) 1972-03-30 1977-08-01
US4097483A (en) 1974-11-01 1978-06-27 Kyorin Pharmaceutical Co., Ltd. Pyrazolo 1,5-a!pyridines
JPS6263520A (ja) * 1985-09-14 1987-03-20 Kyorin Pharmaceut Co Ltd 抗リウマチ剤
WO1996041626A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
ES2326893T3 (es) * 1998-05-27 2009-10-21 Genzyme Corporation Vectores aav para la fabricacion de medicamentos para administracion potenciada por conveccion.
CA2319495A1 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
WO2000009127A1 (fr) * 1998-08-10 2000-02-24 Kyorin Pharmaceutical Co., Ltd. Traitements contre la sclerose en plaques
US20020068740A1 (en) * 1999-12-07 2002-06-06 Mylari Banavara L. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications
US7135495B2 (en) * 2000-03-09 2006-11-14 Ono Pharmaceutical Co., Ltd. Indole derivatives
WO2001074811A2 (en) * 2000-03-30 2001-10-11 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
ATE509904T1 (de) * 2000-09-14 2011-06-15 Mitsubishi Tanabe Pharma Corp Neue amidverbindungen und deren medizinische verwendung
US20020137755A1 (en) * 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
DE20020546U1 (de) * 2000-12-04 2002-04-11 Zumtobel Staff Gmbh Fassung für Kompaktleuchtstofflampen
CA2431206C (en) * 2000-12-08 2009-09-01 Takeda Chemical Industries, Ltd. Combination drugs containing anti-sepsis cycloalkene compound
US20040097555A1 (en) * 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
EP1402900A1 (en) * 2001-06-11 2004-03-31 Takeda Chemical Industries, Ltd. Medicinal compositions
JP2004538305A (ja) * 2001-07-31 2004-12-24 ファルマシア・アンド・アップジョン・カンパニー ３−ヘテロシクリル−及び３−シクロアルキル−３−アリールオキシプロパンアミンによる慢性疼痛の治療
JP5137289B2 (ja) * 2001-08-03 2013-02-06 武田薬品工業株式会社 安定な乳化組成物
CA2456754A1 (en) * 2001-08-08 2003-02-20 Yuji Iizawa Benzazepine derivative, process for producing the same, and use
CA2457482A1 (en) * 2001-08-09 2003-02-27 Kissei Pharmaceutical Co., Ltd. 5-amidino-n-(2-aminophenethyl)-2-hydroxybenzenesulfonamide derivative, medicinal composition containing the same, and intermediate therefor
US7338939B2 (en) * 2003-09-30 2008-03-04 New River Pharmaceuticals Inc. Abuse-resistant hydrocodone compounds
WO2003022813A1 (fr) * 2001-09-07 2003-03-20 Ono Pharmaceutical Co., Ltd. Derives indole, methode de fabrication et medicaments renfermant lesdits derives en tant que principe actif
CA2464763A1 (en) * 2001-11-09 2003-05-15 Kissei Pharmaceutical Co., Ltd. 5-amidino-2-hydroxybenzenesulfonamide derivatives, medicinal compositions containing the same, medicinal use thereof and intermediates in the production thereof
KR100704215B1 (ko) * 2002-03-05 2007-04-10 오노 야꾸힝 고교 가부시키가이샤 8-아자프로스타글란딘 유도체 화합물 및 그 화합물을 유효성분으로서 함유하는 약제
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US20050038063A1 (en) * 2002-11-29 2005-02-17 Kenneth Newman Method of treating acute pain with unitary dosage form comprising ibuprofen and oxycodone
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
CL2004000544A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati
WO2004100871A2 (en) * 2003-05-09 2004-11-25 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
US7261882B2 (en) * 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US7534806B2 (en) * 2004-12-06 2009-05-19 Avigen, Inc. Method for treating neuropathic pain and associated syndromes
MX2007015789A (es) * 2005-06-16 2008-02-15 Mallinckrodt Inc Nueva ruta de sintesis para opiatos de 14-hidroxilo a traves de 1-halo-tebaina o analogos.
PL1928438T3 (pl) * 2005-09-26 2013-08-30 Avigen Inc Zastosowanie ibudilastu do leczenia uzależnień od środków odurzających
CA2653345A1 (en) * 2006-05-31 2007-12-13 Avigen, Inc. Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity
AU2007258567B2 (en) * 2006-06-06 2012-04-19 Medicinova, Inc. Substituted pyrazolo (1,5-alpha) pyridine compounds and their methods of use
CA2669463A1 (en) * 2006-11-09 2008-05-15 Avigen, Inc. Method for treating delirium

Also Published As

Publication number Publication date
WO2008094571A1 (en) 2008-08-07
PT2131841E (pt) 2012-09-24
ES2392116T3 (es) 2012-12-04
EP2131841B1 (en) 2012-08-01
HK1139856A1 (en) 2010-09-30
US20080181876A1 (en) 2008-07-31
DK2131841T3 (da) 2012-10-15
EP2131841A1 (en) 2009-12-16

Similar Documents

Publication Publication Date Title
IL257418A (en) Methods for treating addiction
IL212348A0 (en) Treatment method
GB0714363D0 (en) Treatment apparatus
GB0606604D0 (en) Treatment apparatus
EP2219449A4 (en) METHOD FOR THE TREATMENT OF EXPOSURE TO DAMAGING
EP2083857A4 (en) METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA
IL213619A0 (en) Treatment
GB0802116D0 (en) Treatment
EP2282826A4 (en) PROCESS FOR TREATMENT OF ODOR
HK1255227A1 (zh) 疼痛治療
EP2184598A4 (en) FABRIC PIECE TREATMENT DEVICE
GB0822011D0 (en) Treatment
HK1139856A1 (en) Methods for treating acute pain
IL204728A0 (en) Methods and compounds for treating retinol-related diseases
GB0711342D0 (en) Well treatment
EP2341936A4 (en) METHOD FOR TREATING OR PREVENTING IL-1ß-CONTAINED ILLNESSES
IL238394A0 (en) Cancer treatment method
GB0811992D0 (en) Treatment
EP2144888A4 (en) METHODS OF TREATING CANCER
GB0718684D0 (en) Treatment method
EP2088862A4 (en) METHOD OF TREATING CANCER
EP2182884A4 (en) TREATMENT APPARATUS
HK1110262A1 (en) Waste treatment method
GB0716784D0 (en) Well treatment
GB0820972D0 (en) Treatment